Israel

Kamada

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Kamada and Kedrion Biopharma Join Hands to Develop, Manufacture and Distribute Plasma Based Anti-SARS-CoV-2 Polyclonal IgG Product

Lead Product(s): Anti-SARS-CoV-2 polyclonal immunoglobulin

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Kedrion

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 27, 2020

Details:

Kedrion will supply plasma from convalescent COVID-19. Kamada will be responsible for development, manufacturing and distribution of the product in territories not under kedrion’s responsibility.

MigVax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

OurCrowd Leads $12 Million Investment Round in Israeli COVID-19 Vaccine Company MigVax

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: OurCrowd

Deal Size: $12.0 million Upfront Cash: Undisclosed

Deal Type: Financing April 22, 2020

Details:

Investment will accelerate path to clinical trials and bring Israel’s human coronavirus vaccine to market.

RedHill Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Initial Data Shows Improvement In Covid-19 With Redhill’s Opaganib

Lead Product(s): Opaganib,Hydroxychloroquine Sulphate

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

Details:

Opaganib was administered in addition to standard-of-care, including hydroxychloroquine background therapy, and was well tolerated.

SuperTrans Medical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Korean firm invests $2M in SuperTrans Medical

Lead Product(s): Antibiotics

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Mediforum Pharm

Deal Size: $2.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration April 10, 2020

Details:

SuperTrans is completing a candidate evaluation of COVID-19 therapy based on its transmission technology.

Pluristem Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Pluristem and Charité University of Medicine Berlin Join Forces Targeting COVID-19 Treatment

Lead Product(s): PLX cells

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 12, 2020

Details:

Pre-clinical findings of PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal in COVID-19 infection.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Kamada

Kamada and Kedrion Biopharma Join Hands to Develop, Manufacture and Distribute Plasma Based Anti-SARS-CoV-2 Polyclonal IgG Product

MigVax

OurCrowd Leads $12 Million Investment Round in Israeli COVID-19 Vaccine Company MigVax

RedHill Biopharma

Initial Data Shows Improvement In Covid-19 With Redhill’s Opaganib

SuperTrans Medical

Korean firm invests $2M in SuperTrans Medical

Pluristem Therapeutics

Pluristem and Charité University of Medicine Berlin Join Forces Targeting COVID-19 Treatment